
Hubble Network launches Bluetooth satellite system for tracking your devices from orbit
An artist's conception shows one of Hubble Network's satellites in orbit. (Hubble Network illustration)
A Seattle space startup called Hubble Network is unveiling a system that uses satellites and low-power Bluetooth signals to monitor devices and sensors around the globe.
The system, known as the Hubble BLE Finding Network, can open the way for applications ranging from locating lost pets to monitoring supply chains and watching out for wildfires, Hubble Network CEO and co-founder Alex Haro said.
'Agriculture, oil and gas, mining, defense … There are all these important verticals and industries where there is need for this very battery- and cost-efficient network that can have global accessibility,' Haro told GeekWire.
Hubble's network could be regarded as a low-cost, low-power GPS alternative for Bluetooth devices.
Over the past decade, consumers have become familiar with finding services such as Apple's 'Find My' app and Google's 'Find My Device.' Before he helped found Hubble Network in 2021, Haro himself had a hand in creating the Life360 finding service, which makes use of Bluetooth trackers known as Tiles. His current venture literally adds another dimension to the concept, by going up to low Earth orbit.
Haro and his fellow co-founders created Hubble Network (which has nothing to do with NASA's Hubble Space Telescope) to get around the limitations of today's most commonly used Bluetooth-based tracking devices. The most obvious limitation has to do with range.
'The reason that you and pretty much everyone else thinks about Bluetooth as being so short-range is, that's really what the Bluetooth protocol was designed for,' Haro said. 'It's meant for high-fidelity audio streaming from your computer to your headphones, and so it's operating at millions of bits per second.'
Hubble Network's system turns the dials down on a Bluetooth device's data transmission rate and energy consumption, using a protocol known as Bluetooth Low Energy, or BLE. The company also developed patented technologies for sending messages across distances ranging as far as hundreds of miles — far enough for the messages to be picked up by phased-array antennas on Hubble Network's satellites in space.
Haro compared the approach to enunciating a message quietly and carefully, and repeating the message to make sure it's heard correctly, as opposed to shouting the message as loud as possible. 'On top of that, we give your friend hundreds of microphones that are all focusing their spot beams on you,' he said. 'That's what allows it to pick up that directed energy and be able to hear you, even with a lot of other noise happening all around you.'
In collaboration with Spire Global, Hubble Network's first two satellites were launched last year, and the Bluetooth space connection was successfully tested just weeks after that initial launch. Now the Hubble Network constellation has grown to seven satellites. (The four newest satellites are nicknamed Lilo and Stitch, Scooby and Shaggy.) The company aims to expand its constellation to 60 satellites by 2028.
Hubble Network's business model calls for adding satellite connectivity to existing tracking applications that are offered by other companies — including Life360, which has more than 80 million monthly active users. The Hubble BLE Network can leverage Life360's devices as well as millions of other IoT devices that have embedded BLE chips. Anyone who uses such devices to, say, monitor their supply chains or check up on their crops can sign up to join the network.
'With a simple SDK change on our customers' devices, they can access 100 million gateways, but they also have access to the satellite network,' Haro said.
He emphasized that the IoT data is encrypted end-to-end. 'Not even Hubble can tell what our customers' data is,' Haro said. 'It really is owned by our customer. It's the responsibility of our customer to make sure that these products are being used for proper enterprise use cases and not for any forms of harassment or any other bad actors. We're basically acting like a carrier for our customers' devices.'
When Haro talks about customers, he's talking about companies that are using — or will be using — Hubble's service to provide low-cost satellite connectivity for their Bluetooth devices. It's up to those companies to decide how their customers will cover the cost of the service, or how they'll account for the cost internally.
'We have a number of customers that are currently in the pilot phase and are converting over to contracted customers,' Haro said. 'So we will have some hopefully fun announcements over the next few months.'
Four years into its existence, Hubble Network has about 50 employees, including about 35 in Seattle and a 'big contingent in the Bay Area,' according to Haro. He said the company has officially brought in $30 million in investment so far, highlighted by a $20 million Series A funding round in 2023.
The months ahead are likely to bring further developments on the business frontier as well as on the final frontier. In more ways than one, when it comes to Hubble Network's future, watch this space.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Biohaven Ltd. (BHVN) Collaborates with Bexorg, Inc to Target Central Nervous System Disorders
Biohaven Ltd. (NYSE:BHVN) is one of the Best 52-Week Low Stocks to Buy According to Analysts.. On June 10, Biohaven Ltd. (NYSE:BHVN) announced that it has started a research collaboration with Bexorg, Inc. targeting central nervous system disorders. Bexorg, which is a techbio company, has a platform that can revive and study whole human and pig brains using artificial blood. This technology helps them see how drugs affect actual brain tissue. The platform produces deep data about how genes and proteins behave in disease and health. A pharmacist in a white coat with a range of drugs on shelves behind her. Both companies will use this technology to help design and test new therapies for CNS conditions. As a result of this collaboration, two Biohaven Ltd. (NYSE:BHVN) preclinical programs will benefit from these unique brain studies. Bexorg's approach offers a big leap ahead of normal lab models. Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company that develops and commercializes treatments for diseases in immunology, neuroscience, and oncology. While we acknowledge the potential of BHVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
Sparrow expands coverage to five U.S. states, making it easier than ever for Americans to claim missing money
Now available in Pennsylvania, Sparrow expands its secure, automated missing money platform to five states — with more on the way NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Sparrow, the secure platform that helps Americans claim missing money in minutes, has officially expanded to five states — with Pennsylvania the newest addition. The company's fully automated service now supports residents in California, Texas, Wisconsin, Nebraska, and Pennsylvania, with additional support for Georgia and Florida coming soon. With over $80 billion in unclaimed funds sitting idle — and 1 in 7 Americans estimated to have missing money — Sparrow offers a fast, safe, and frustration-free way to recover what's rightfully yours. Using cutting-edge technology and real-time financial data, Sparrow verifies your identity, retrieves the necessary documents on your behalf, and prepares your claim with minimal effort required. What used to take days — and often involved printing, mailing, or even visiting a notary — now takes most users under five minutes. 'We built Sparrow because the process of claiming lost money felt unnecessarily hard for everyday people,' said Will Nemirovsky, CEO. 'I ran into it myself in 2024, trying to claim a small refund — and it took hours of paperwork and frustration. We knew we could make it effortless and secure using modern technology and automation. Expanding to Pennsylvania is especially meaningful for me —it's where I met my Co-Founder, Jack Goettle.' Sparrow is fully licensed, offers risk-free pricing, and is committed to bank-grade encryption and secure data handling. Claims are processed through streamlined workflows that minimize human error and eliminate guesswork. Behind the scenes is a team of fintech veterans working to modernize a system that has failed everyday consumers for decades. To date, Sparrow has already helped users reclaim millions of dollars — and they're just getting started. Sparrow offers a success-based model: if your claim isn't paid, you don't pay. Check if you're owed money — it only takes a few minutes. Visit to get started. media@ Photos accompanying this announcement are available at: in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On July 14, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), while lowering the price target from $80 to $79. The firm held its positive outlook even after the recent challenge from the FDA's complete response letter for UX111 in Sanfilippo syndrome. The CRL was focused on specific chemistry, manufacturing, and controls issues. Importantly, the clinical data for UX111 was not questioned; however, the approval is still achievable once the CMC issues are resolved. A research team in a laboratory peering through microscopes at a biologic product. The analyst noted that the company is responding quickly and plans to address the CMC concerns and resubmit its Biologics License Application in the coming months. The analyst is also optimistic due to Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) robust pipeline. The company has promising programs for conditions like osteogenesis imperfecta and Angelman syndrome. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) develops treatments for rare and ultra-rare genetic diseases. They focus on biologics, small molecules, gene therapy, and nucleic acid products. While we acknowledge the potential of RARE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.